Why is Ipamorelin considered a 'clean' secretagogue?

Ipamorelin is highly selective for the ghrelin receptor and, in research, releases GH without the significant cortisol, prolactin, or aldosterone increases seen with older peptides like GHRP-6.

Is this blend commonly used as a beginner GH secretagogue stack?

In research contexts, the Sermorelin / Ipamorelin combination is frequently characterized as a foundational, low-side-effect GH secretagogue pairing.

← All peptides

Growth Hormone Secretagogues

Research Chemical

Sermorelin / Ipamorelin Blend

Also known as: Sermorelin & Ipamorelin, Sermorelin + Ipamorelin Blend

A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.

Mechanism of Action

Sermorelin (GHRH 1-29) stimulates the pituitary GHRH receptor to drive growth hormone synthesis and pulsatile release. Ipamorelin is a selective GHS-R1a (ghrelin) receptor agonist that triggers an additional GH pulse without meaningfully elevating cortisol, prolactin, or aldosterone, giving it a cleaner profile than older GHRPs. Acting on two separate receptors, the pair produces a synergistic GH response while preserving physiologic feedback and the natural pulsatile pattern.

Half-life: Mixed: Sermorelin ~10-20 minutes, Ipamorelin ~2 hours
Administration Routes: subcutaneous
Research Status: Research Chemical